|
1
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-Small-Cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-Small-Cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rittmeyer A, Barlesi F, Waterkamp D, Park
K, Ciardiello F, Von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols
MC, et al: Atezolizumab versus docetaxel in patients with
previously treated non-small-cell lung cancer (OAK): A phase 3,
open-label, multicentre randomised controlled trial. Lancet.
389:255–265. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho
BC, Turna HZ, Castro G, Srimuninnimit V, Laktionov KK, Bondarenko
I, et al: Pembrolizumab versus chemotherapy for previously
untreated, PD-L1-expressing, locally advanced or metastatic
non-small-cell lung cancer (KEYNOTE-042): A randomised, Open-label,
controlled, phase 3 trial. Lancet. 393:1819–1830. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Asano Y, Yamamoto N, Demura S, Hayashi K,
Takeuchi A, Kato S, Miwa S, Igarashi K, Higuchi T, Yonezawa H, et
al: The therapeutic effect and clinical outcome of immune
checkpoint inhibitors on bone metastasis in advanced non-small-cell
lung cancer. Front Oncol. 12:8716752022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Asano Y, Yamamoto N, Demura S, Hayashi K,
Takeuchi A, Kato S, Miwa S, Igarashi K, Higuchi T, Taniguchi Y, et
al: Combination therapy with immune checkpoint inhibitors and
denosumab improves clinical outcomes in non-small cell lung cancer
with bone metastases. Lung Cancer. 193:1078582024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Asano Y, Yamamoto N and Demura S, Takeuchi
A, Kato S, Miwa S, Okuda M, Matsumoto I, Yano S and Demura S: Serum
inflammatory dynamics as novel biomarkers for immune checkpoint
inhibitors in non-small-cell lung cancer with bone metastases.
Anticancer Res. 44:4493–4503. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Asano Y, Yamamoto N, Hayashi K, Hayashi K,
Takeuchi A, Kato S, Miwa S, Igarashi K, Higuchi T, Taniguchi Y, et
al: Novel predictors of immune checkpoint inhibitor response and
prognosis in advanced non-small-cell lung cancer with bone
metastasis. Cancer Med. 12:12425–12437. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Asano Y, Hayashi K, Takeuchi A, Kato S,
Miwa S, Taniguchi Y, Okuda M, Matsumoto I, Yano S and Demura S:
Combining dynamics of serum inflammatory and nutritional indicators
as novel biomarkers in immune checkpoint inhibitor treatment of
non-small-cell lung cancer with bone metastases. Int
Immunopharmacol. 136:1122762024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kawachi H, Tamiya M, Tamiya A, Ishii S,
Hirano K, Matsumoto H, Fukuda Y, Yokoyama T, Kominami R, Fujimoto
D, et al: Association between metastatic sites and first-line
pembrolizumab treatment outcome for advanced non-small cell lung
cancer with high PD-L1 expression: A retrospective multicenter
cohort study. Invest New Drugs. 38:211–218. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Landi L, D'Incà F, Gelibter A, Chiari R,
Grossi F, Delmonte A, Passaro A, Signorelli D, Gelsomino F, Galetta
D, et al: Bone metastases and immunotherapy in patients with
advanced non-small-cell lung cancer. J Immunother Cancer.
7:3162019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yin M, Guan S, Ding X, Zhuang R, Sun Z,
Wang T, Zheng J, Li L, Gao X, Wei H, et al: Construction and
validation of a novel web-based nomogram for patients with lung
cancer with bone metastasis: A real-world analysis based on the
SEER database. Front Oncol. 12:10752172022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Demaria S and Formenti SC: The abscopal
effect 67 years later: From a side story to center stage. Br J
Radiol. 93:202000422020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Walle T, Martinez Monge R, Cerwenka A,
Ajona D, Melero I and Lecanda F: Radiation effects on antitumor
immune responses: Current perspectives and challenges. Ther Adv Med
Oncol. 10:17588340177425752018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Morita Y, Saijo A, Nokihara H, Mitsuhashi
A, Yoneda H, Otsuka K, Ogino H, Bando Y and Nishioka Y: Radiation
therapy induces an abscopal effect and upregulates programmed
death-ligand 1 expression in a patient with non-small cell lung
cancer. Thorac Cancer. 13:1079–1082. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bang A and Schoenfeld JD: Immunotherapy
and radiotherapy for metastatic cancers. Ann Palliat Med.
8:312–325. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xing D, Siva S and Hanna GG: The abscopal
effect of stereotactic radiotherapy and immunotherapy: Fool's Gold
or El Dorado? Clin Oncol. 31:432–443. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fiorica F, Tebano U, Gabbani M, Perrone M,
Missiroli S, Berretta M, Giuliani J, Bonetti A, Remo A, Pigozzi E,
et al: Beyond abscopal effect: A meta-analysis of immune checkpoint
inhibitors and radiotherapy in advanced non-small cell lung cancer.
Cancers (Basel). 13:23522021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng Y, Liu X, Li N, Zhao A, Sun Z, Wang
M and Luo J: Radiotherapy combined with immunotherapy could improve
the immune infiltration of melanoma in mice and enhance the
abscopal effect. Radiat Oncol J. 41:129–139. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wei J, Montalvo-Ortiz W, Yu L, Krasco A,
Ebstein S, Cortez C, Lowy I, Murphy AJ, Sleeman MA and Skokos D:
Sequence of alphaPD-1 relative to local tumor irradiation
determines the induction of abscopal antitumor immune responses.
Sci Immunol. 6:eabg01172021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Park B, Yee C and Lee KM: The effect of
radiation on the immune response to cancers. Int J Mol Sci.
15:927–943. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mondini M, Levy A, Meziani L, Milliat F
and Deutsch E: Radiotherapy-immunotherapy combinations-Perspectives
and challenges. Mol Oncol. 14:1529–1537. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Antonia SJ, Villegas A, Daniel D, Vicente
D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, De Wit M, et
al: Overall survival with durvalumab after chemoradiotherapy in
stage III NSCLC. N Engl J Med. 379:2342–2350. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gray JE, Villegas A, Daniel D, Vicente D,
Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, Cho BC, et al:
Three-year overall survival with durvalumab after chemoradiotherapy
in stage III NSCLC-update from PACIFIC. J Thorac Oncol. 15:288–293.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Theelen WSME, Peulen HMU, Lalezari F, van
der Noort V, De Vries JF, Aerts JG, Dumoulin DW, Bahce I, Niemeijer
AL, De Langen AJ, et al: Effect of pembrolizumab after stereotactic
Body radiotherapy vs. pembrolizumab alone on tumor response in
patients with advanced non-small cell lung cancer: Results of the
PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol.
5:1276–1282. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shaverdian N, Lisberg AE, Bornazyan K,
Veruttipong D, Goldman JW, Formenti SC, Garon EB and Lee P:
Previous radiotherapy and the clinical activity and toxicity of
pembrolizumab in the treatment of Non-small-cell lung cancer: A
secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol.
18:895–903. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bates JE, Morris CG, Milano MT, Yeung AR
and Hoppe BS: Immunotherapy with hypofractionated radiotherapy in
metastatic non-small cell lung cancer: An analysis of the National
Cancer Database. Radiother Oncol. 138:75–79. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Foster CC, Sher DJ, Rusthoven CG, Verma V,
Spiotto MT, Weichselbaum RR and Koshy M: Overall survival according
to immunotherapy and radiation treatment for metastatic
non-small-cell lung cancer: A National Cancer Database analysis.
Radiat Oncol. 14:182019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Welsh J, Menon H, Chen D, Verma V, Tang C,
Altan M, Hess K, De Groot P, Nguyen QN, Varghese R, et al:
Pembrolizumab with or without radiation therapy for metastatic
non-small cell lung cancer: A randomized phase I/II trial. J
Immunother Cancer. 8:e0010012020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Theelen WSME, Chen D, Verma V, Hobbs BP,
Peulen HM, Aerts JG, Bahce I, Niemeijer AL, Chang JY, de Groot PM,
et al: Pembrolizumab with or without radiotherapy for metastatic
non-small-cell lung cancer: A pooled analysis of two randomised
trials. Lancet Respir Med. 9:467–475. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu Z, Xu T, Chang P, Fu W, Wei J, Xia C,
Wang Q, Li M, Pu X, Huang F, et al: Efficacy and safety of immune
checkpoint inhibitors with or without radiotherapy in metastatic
non-small cell lung cancer: A systematic review and meta-analysis.
Front Pharmacol. 14:10642272023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tomaciello M, Conte M, Montinaro FR,
Sabatini A, Cunicella G, Di Giammarco F, Tini P, Gravina GL,
Cortesi E, Minniti G, et al: Abscopal effect on bone metastases
from solid tumors: A systematic review and retrospective analysis
of challenge within a challenge. Biomedicines. 11:11572023.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rodríguez Plá M, Dualde Beltrán D and
Ferrer Albiach E: Immune checkpoints inhibitors and SRS/SBRT
synergy in metastatic non-small-cell lung cancer and melanoma: A
systematic review. Int J Mol Sci. 22:116212021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Geng Y, Zhang Q, Feng S, Li C, Wang L,
Zhao X, Yang Z, Li Z, Luo H, Liu R, et al: Safety and efficacy of
PD-1/PD-L1 inhibitors combined with radiotherapy in patients with
non-small-cell lung cancer: A systematic review and meta-analysis.
Cancer Med. 10:1222–1239. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kan C, Vargas G, Le Pape F and Clézardin
P: Cancer cell colonisation in the bone microenvironment. Int J Mol
Sci. 17:16742016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Santini D, Barni S, Intagliata S, Falcone
A, Ferraù F, Galetta D, Moscetti L, La Verde N, Ibrahim T, Petrelli
F, et al: Natural history of non-small-cell lung cancer with bone
metastases. Sci Rep. 5:186702015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lutz S, Balboni T, Jones J, Lo S, Petit J,
Rich SE, Wong R and Hahn C: Palliative radiation therapy for bone
metastases: Update of an ASTRO Evidence-Based Guideline. Pract
Radiat Oncol. 7:4–12. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Makita K, Hamamoto Y, Kanzaki H, Kataoka
M, Yamamoto S, Nagasaki K, Ishikawa H, Takata N, Tsuruoka S, Uwatsu
K, et al: Local control of bone metastases treated with external
beam radiotherapy in recent years: A multicenter retrospective
study. Radiat Oncol. 16:2252021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
LeVasseur N, Clemons M, Hutton B, Shorr R
and Jacobs C: Bone-targeted therapy use in patients with bone
metastases from lung cancer: A systematic review of randomized
controlled trials. Cancer Treat Rev. 50:183–193. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Facilissimo I, Natoli G, Gaspari F,
Comandone T, Bongiovanni D, Gollini P, Provenza C and Comandone A:
The role of bone radiotherapy during immune checkpoint inhibitors
treatment of non-small-cell lung cancer: A single-institution
experience. Ther Adv Med Oncol. 17:175883592513324512025.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jayathilaka B, Mian F, Franchini F,
Au-Yeung G and IJzerman M: Cancer and treatment specific incidence
rates of immune-related adverse events induced by immune checkpoint
inhibitors: A systematic review. Br J Cancer. 132:51–57. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Suazo-Zepeda E, Bokern M, Vinke PC,
Hiltermann TJ, De Bock GH and Sidorenkov G: Risk factors for
adverse events induced by immune checkpoint inhibitors in patients
with non-small-cell lung cancer: A systematic review and
meta-analysis. Cancer Immunol Immunother. 70:3069–3080. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dang TO, Ogunniyi A, Barbee MS and Drilon
A: Pembrolizumab for the treatment of PD-L1 positive advanced or
metastatic Non-small cell lung cancer. Expert Rev Anticancer Ther.
16:13–20. 2016. View Article : Google Scholar : PubMed/NCBI
|
